ArticleAnnals of surgical oncology2026
The Impact of Surgery and Survival Prediction on Patients with Locally Advanced Gastric-type Endocervical Adenocarcinoma: A Population-Based Cohort Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThis study aimed to examine the clinical characteristics of gastric-type endocervical adenocarcinoma (GEA-C) and the main factors affecting prognosis, and to investigate the effect of surgical treatment on the prognosis of patients with GEA-C.
methodsIn this study, clinicopathologic data of GEA-C were collected from the Surveillance, Epidemiology, and End Results (SEER) database (2000-2019). Multivariate Cox regression analysis, Kaplan-Meier survival analysis, and the log-rank test were used to assess the effect of surgical interventions on different subgroups in the overall survival (OS) of patients with GEA-C.
resultsIn the overall cohort, the surgical group demonstrated significantly better OS than the non-surgical group (79.6% vs 38.2%; p < 0.001). This survival advantage persisted after propensity score-matching (PSM) (79.6% vs 47.4%; p < 0.001). Among the patients with locally advanced disease, the OS rates were 64.6% versus 43.8% (p = 0.040) favoring surgery, with the disparity further accentuated after PSM (64.6% vs 12.5%; p < 0.001). Subgroup analyses confirmed sustained survival benefits with surgery across all strata, including age (≤50 years: 88.5% vs 30.8% [p < 0.001]; >50 years: 64.8% vs 42.9% [p = 0.009]) and tumor size (<6 cm: 84.4% vs 57.1% [p < 0.001]; ≥6 cm: 57.1% vs 20.0% [p = 0.004]). Notably, when combined with chemoradiotherapy, surgery achieved significantly higher OS rates than chemoradiotherapy alone (64.3% vs 37.0%; p = 0.002).
conclusionSurgical management is associated with significantly improved OS in GEA-C, especially among patients presenting with locally advanced disease. The integration of surgery with chemoradiotherapy demonstrated potentially enhanced therapeutic efficacy relative to chemoradiotherapy as a stand-alone approach.
Indexed as
Identifiers
42420638What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.